CMP (Comprehensive Metabolic Panel): Which Tests to Order Alongside

What a CMP Actually Measures

The comprehensive metabolic panel reports 14 analytes in a single blood draw. It covers three metabolic domains: glucose metabolism, kidney filtration, and hepatic function, with an electrolyte overlay that flags acid-base disturbances.

Glucose and Protein Markers

Fasting glucose is the panel's primary metabolic screening value. The American Diabetes Association (ADA) defines normal fasting plasma glucose as <100 mg/dL, with 100 to 125 mg/dL indicating prediabetes. Albumin (3.5 to 5.5 g/dL) and total protein (6.0 to 8.3 g/dL) reflect nutritional status and synthetic liver capacity. A low albumin on an otherwise normal CMP may point toward chronic inflammation, nephrotic syndrome, or malnutrition rather than acute liver disease.

Kidney Function Analytes

Blood urea nitrogen (BUN) and creatinine together estimate glomerular filtration. The National Kidney Foundation recommends using the CKD-EPI equation to convert creatinine into an estimated GFR (eGFR). A creatinine of 1.4 mg/dL in a 70-year-old male translates to a very different eGFR than the same value in a 30-year-old. BUN-to-creatinine ratio above 20:1 may suggest prerenal azotemia from dehydration rather than intrinsic kidney disease.

Liver Enzymes and Bilirubin

ALT, AST, and alkaline phosphatase (ALP) form the hepatic component. The American College of Gastroenterology (ACG) notes that ALT is more liver-specific than AST. An AST:ALT ratio greater than 2:1 raises suspicion for alcohol-related liver injury. Total bilirubin above 1.2 mg/dL can indicate hemolysis, Gilbert syndrome, or biliary obstruction depending on the fractionated (direct vs. Indirect) result, which the CMP does not include.

Electrolytes and CO2

Sodium, potassium, chloride, and CO2 (bicarbonate) complete the panel. These four values define acid-base status. A CO2 below 22 mmol/L with a normal anion gap may indicate renal tubular acidosis, while a CO2 above 29 mmol/L may reflect compensated respiratory acidosis or metabolic alkalosis from diuretic use.

Why a CMP Alone Is Not Enough

A CMP is broad but shallow. It reports fasting glucose but not HbA1c, so it misses glycemic trends over 90 days. It reports creatinine but not cystatin C, so eGFR estimates lose precision in patients with high or low muscle mass. It reports liver enzymes but not GGT, so alcohol-related hepatotoxicity can be under-detected.

Clinical Blind Spots

No hematology data appears on a CMP. Anemia, thrombocytopenia, and leukocytosis are invisible. No lipid values appear either. A patient with normal glucose and liver enzymes on a CMP could still have an LDL of 190 mg/dL and a triglyceride level of 400 mg/dL. The USPSTF recommends lipid screening for cardiovascular risk assessment in adults aged 40 to 75, and a CMP does not satisfy that screening.

The Cost of Ordering Piecemeal

Ordering a CMP in isolation and then adding tests at a follow-up visit doubles phlebotomy visits and delays clinical decisions. A 2021 analysis published in the Journal of General Internal Medicine found that bundled lab ordering at the initial visit reduced 30-day return rates by 18% compared to sequential ordering. Bundling also lowers aggregate patient cost at most commercial labs.

The Core Paired Tests: What to Add and Why

Five tests pair with a CMP in the majority of primary-care, endocrine, and metabolic health encounters. Each fills a specific gap the CMP leaves open.

CBC (Complete Blood Count)

The CBC is the single most valuable companion to the CMP. It reports white blood cell count, hemoglobin, hematocrit, platelet count, and red cell indices. A low hemoglobin explains an elevated BUN-to-creatinine ratio (GI bleed). A high MCV suggests B12 or folate deficiency. The American Society of Hematology recommends CBC as part of baseline evaluation for unexplained fatigue, which is one of the most common reasons patients receive a CMP in the first place. CPT code 85025. Typical add-on cost: $5 to $15.

Lipid Panel

A standard lipid panel reports total cholesterol, LDL, HDL, and triglycerides. The ACC/AHA 2018 cholesterol guidelines use LDL-C as the primary target for statin therapy initiation. When drawn fasting alongside a CMP, the lipid panel requires no additional prep from the patient. Non-fasting lipid panels are acceptable per 2016 European guidance, but a fasting draw gives the most accurate triglyceride reading. CPT code 80061.

HbA1c

HbA1c reflects average blood glucose over the prior 8 to 12 weeks. Fasting glucose on a CMP is a single time point and can be normal in early type 2 diabetes when postprandial spikes have not yet raised fasting levels. The ADA Standards of Care 2024 accepts HbA1c of 5.7% to 6.4% as diagnostic for prediabetes and 6.5% or above for diabetes. CPT code 83036. Cost: $10 to $30.

TSH (Thyroid-Stimulating Hormone)

Thyroid dysfunction affects glucose, cholesterol, and liver enzymes. All three appear on a CMP, but none will identify the thyroid as the upstream cause without TSH. The American Thyroid Association recommends TSH screening in adults over 35 every five years, with more frequent testing in patients on levothyroxine or with autoimmune risk factors. A TSH above 4.5 mIU/L with a normal CMP glucose but borderline-high LDL often points to subclinical hypothyroidism. CPT code 84443.

Urinalysis

Creatinine on the CMP estimates kidney function, but urinalysis detects what creatinine misses: proteinuria, hematuria, and glucosuria. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines recommend urine albumin-to-creatinine ratio (UACR) alongside serum creatinine for complete CKD staging. A patient with an eGFR of 65 and a UACR of 300 mg/g has stage 3a CKD with severely increased albuminuria, a classification impossible without the urine specimen.

Condition-Specific Add-Ons

Beyond the five core pairings, specific clinical scenarios call for targeted additions to the CMP.

Hormone Therapy Monitoring

Patients on testosterone replacement therapy (TRT) need a CMP for liver enzymes and glucose, but the Endocrine Society 2018 guidelines also require total testosterone, free testosterone, hematocrit (from the CBC), and PSA at baseline and at 3, 6, and 12 months. Estradiol may be added if symptoms of aromatization appear. For women on HRT, the CMP liver panel serves as a safety check for oral estrogen, but FSH and estradiol are needed to confirm menopausal status and dose adequacy.

GLP-1 and Weight-Management Programs

Patients on semaglutide, tirzepatide, or other GLP-1 receptor agonists benefit from a CMP at baseline and every 3 to 6 months to track glucose normalization and liver enzyme trends. Add HbA1c (to track glycemic response), lipid panel (LDL often drops 10% to 15% with significant weight loss per STEP-1 data, N=1,961), and a CBC to monitor for the rare but reported thrombocytopenia signal. Patients with pre-existing MASLD should also receive GGT and a FibroScan referral if ALT remains elevated above 40 U/L after 6 months.

Thyroid Disorder Workups

When a CMP shows unexplained hypercalcemia (calcium above 10.5 mg/dL), the differential includes primary hyperparathyroidism. Add intact PTH and 25-hydroxyvitamin D. When TSH returns abnormal, add free T4 and free T3. The American Association of Clinical Endocrinology (AACE) recommends TPO antibodies if TSH is above 10 mIU/L or if the patient has a goiter on exam, to distinguish Hashimoto thyroiditis from other causes.

Cardiovascular Risk Stratification

A CMP plus lipid panel covers the basics. For patients with a 10-year ASCVD risk between 5% and 20% (the "borderline" zone in the ACC/AHA pooled cohort equations), adding high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a) helps reclassify risk. The 2018 ACC/AHA guidelines call these "risk-enhancing factors." An Lp(a) above 50 mg/dL or 125 nmol/L tips the decision toward statin initiation in patients whose LDL alone does not meet the threshold.

Reading CMP Results: Normal Ranges and Red Flags

Interpreting a CMP requires pattern recognition across all 14 values, not isolated flagging of highs and lows.

What "Normal" Means on a CMP

Reference ranges vary slightly by lab, but consensus values from the Mayo Clinic reference laboratory and the AACE cluster tightly. Glucose: 70 to 100 mg/dL fasting. Sodium: 136 to 145 mmol/L. Potassium: 3.5 to 5.0 mmol/L. Calcium: 8.5 to 10.5 mg/dL. BUN: 7 to 20 mg/dL. Creatinine: 0.7 to 1.3 mg/dL (male), 0.6 to 1.1 mg/dL (female). ALT: 7 to 56 U/L. AST: 10 to 40 U/L. ALP: 44 to 147 U/L. Total bilirubin: 0.1 to 1.2 mg/dL.

Patterns That Signal Action

A high glucose (above 126 mg/dL fasting on two occasions) with a normal ALT and normal creatinine is straightforward diabetes. A high glucose with elevated ALT and elevated AST raises concern for MASLD-related insulin resistance. Low sodium (below 130 mmol/L) with low BUN may indicate SIADH or overhydration. High calcium with low phosphorus (not on the CMP but available on a BMP add-on) points to hyperparathyroidism. Elevated ALP with normal ALT and AST is more likely bone origin than liver origin, especially in postmenopausal women or adolescents.

When to Repeat vs. When to Escalate

A single mildly abnormal value (potassium of 5.1, ALT of 60) warrants a repeat draw in 2 to 4 weeks with clinical correlation. Critically abnormal values require same-day action. The National Academy of Clinical Biochemistry defines critical potassium as <3.0 or above 6.0 mmol/L, critical sodium as <120 or above 160 mmol/L, and critical glucose as <50 or above 450 mg/dL.

How to Lower or Raise Abnormal CMP Values

Because the CMP spans multiple organ systems, "lowering" or "raising" a CMP result depends entirely on which analyte is abnormal.

Glucose Management

Elevated fasting glucose responds to caloric restriction, increased physical activity, metformin (first-line per ADA 2024 Standards of Care), and GLP-1 receptor agonists for patients with obesity or established cardiovascular disease. A fasting glucose below 70 mg/dL in a non-diabetic patient warrants workup for insulinoma (fasting insulin, C-peptide, proinsulin) rather than dietary intervention alone.

Electrolyte Correction

Low potassium (<3.5 mmol/L) is most commonly caused by diuretics, vomiting, or diarrhea. Oral potassium chloride 20 to 40 mEq daily corrects mild hypokalemia. The American Heart Association recommends maintaining potassium between 4.0 and 5.0 mmol/L in patients on digoxin or antiarrhythmics, a tighter window than the standard reference range.

Liver Enzyme Reduction

Elevated ALT and AST from MASLD respond to weight loss of 7% to 10% of body weight, as demonstrated in the PIVENS trial (N=247), which showed that vitamin E 800 IU daily reduced ALT in non-diabetic NASH patients. Alcohol cessation normalizes ALT in alcohol-related liver disease within 4 to 8 weeks in most cases. Drug-induced elevations (statins, methotrexate, anti-epileptics) require dose adjustment or substitution.

Ordering Strategy: A Practical Decision Framework

The right panel combination depends on the clinical question. Three ordering tiers cover more than 90% of outpatient scenarios.

Tier 1: Routine Wellness Screen

CMP + CBC + lipid panel + HbA1c + TSH. This five-test bundle answers the broadest range of screening questions for a healthy adult presenting for an annual physical. Total cost at a direct-access lab: $50 to $150 without insurance.

Tier 2: Metabolic or Endocrine Workup

Tier 1 plus free T4, insulin (fasting), UACR, uric acid, and vitamin D. This panel is appropriate for patients with obesity, prediabetes, PCOS, or suspected thyroid disease. It adds roughly $80 to $120 to the Tier 1 cost.

Tier 3: Hormone Therapy Baseline

Tier 2 plus total testosterone, free testosterone (or SHBG for calculation), estradiol, DHEA-S, PSA (males over 40), and prolactin. The Endocrine Society recommends this level of baseline testing before initiating TRT. For women starting HRT, FSH replaces PSA and progesterone is added.

Each tier builds on the previous one. A clinician who starts with Tier 1 and finds an abnormal glucose, suppressed TSH, or elevated ALT can add Tier 2 analytes at the same visit if the blood volume in the original draw tubes allows, avoiding a second phlebotomy.

Timing and Preparation

Fasting status, time of draw, and medication timing all affect CMP accuracy.

Fasting Requirements

A 10- to 12-hour fast is required for accurate fasting glucose. If a lipid panel is drawn simultaneously, the fast also ensures accurate triglyceride values. Water, black coffee, and prescribed medications (unless specifically held) are permitted during the fast. The ADA accepts non-fasting glucose if the clinical question is diabetes screening via HbA1c alone, since HbA1c does not require fasting.

Time-of-Day Effects

Cortisol, testosterone, and TSH all have diurnal variation. The CMP itself is less affected, but if paired tests include hormones, a morning draw (before 10 AM) is preferred. Potassium can be falsely elevated by fist clenching during phlebotomy or by hemolysis during transport, a pre-analytical error that accounts for up to 70% of spurious hyperkalemia results per Clinical Chemistry laboratory data.

Medication Holds

Biotin supplements above 5 mg daily interfere with immunoassay-based tests (TSH, free T4, troponin) but do not affect CMP analytes. The FDA issued a safety communication in 2017 advising patients to stop biotin at least 72 hours before lab draws that include immunoassays. ACE inhibitors and ARBs can raise potassium; this is expected and should not prompt dose changes unless potassium exceeds 5.5 mmol/L on a non-hemolyzed specimen.